
usd may pm et
summari lead manufactur gener pharmaceut produc broad rang tradit
specialti drug sold around world
price-to-earnings oper ep
past perform indic futur perform reli upon
analysi prepar equiti analyst
pm stock trade
target price recent
chang highlight
section stock report updat
invest rationale/risk section
stock report updat shortli
latest news stori marketscop
 lower target
price ep estim --
histor forward price-to-earnings averag due
intens price pressur gener drug
drop ep estim
ep vs
beat consensu revenu
declin yoy north america sale
total europ fall
yoy respect due rapidly-grow
sale new complex gener biosimilar
fail off-set declin commodity-lik
gener rest world sale total
grew yoy strong growth china
sale growth well
expect still think revenu
increas vs strong ramp
gener advair biosimilar neulasta sever
new launch continu
think share attract valu
low end guidanc repres
yield current market cap
growth expect long-term /colin
oper typic drug develop risk includ
uncertainti stem program
regulatori approv process competitior challeng
patent addit legal risk stem on-going
govern investig opioid sale practic
alleg collabor price risk partial
off-set divers gener portfolio product
account revenu
sale come outsid also think
better posit competitor due
success track record first-gener approv
fiscal year end dec ep estim base cfra
oper earn histor earn report
cash dividend paid last year
redistribut reproduct prohibit without written permiss copyright cfra document intend provid person invest advic take account specif invest
object financi situat particular need specif person may receiv report investor seek independ financi advic regard suitabl and/or appropri make
invest implement invest strategi discuss document understand statement regard futur prospect may realiz investor note incom
invest may fluctuat valu invest may rise fall accordingli investor may receiv back less origin invest investor seek advic concern impact
invest may person tax posit tax advisor pleas note public date document may contain specif inform longer current use make
invest decis unless otherwis indic intent updat document
chairman board
corpor profil mylan nv develop licens manufactur market gener drug
biosimilar brand-nam drug over-the-count over-the-counter medicin varieti therapeut
categori approxim market product world-wide custom approxim
countri territori
compani oper three segment north america europ rest world
market compani manufactur sell divers portfolio drug variou form includ oral
solid inject transderm patch gel cream ointment develop drug across varieti
cardiovascular gastroenterolog diabet oncolog diabet among other
product epipen auto-injector use treatment sever allerg reaction
epinephrin auto-injector sold intern anaphylaxi sever allerg
reaction may caus death either swell shut airway signific drop
blood pressur compani launch first author gener epipen auto-injector
drug formul devic function brand-nam product
compani launch gener version copaxon indic relaps form multipl
sclerosi approv gener copaxon requir lengthi patent litig competitor teva
major victori brand drug gener sale
corpor strategi key object capit diversif across mani therapeut
area well across global geographi also plan focu difficult-to-develop gener
specialti pharmaceut well achiev greater economi scale manufactur
compani also seek first gener firm penetr new market captur new product
opportun obtain first-to-fil statu exclus
impact major develop face sever investig relat
price epipen auto-injector compani best sell product octob ceo
heather bresch testifi front congress regard epipen price shortli afterward januari
feder trade commiss file anti-trust investig whether violat anti-trust
law protect epipen competit august reach deal depart
justic regard epipen paid million settlement alleg overcharg
govern epipen misclassifi gener drug avoid pay medicaid rebat result
signific pressur congress consum media launch gener epipen
decemb price discount brand epipen
octob presid rajiv malik identifi target expand lawsuit alleg
price collus across gener drug industri
august acquir sweden-bas meda ab billion inclus net debt believ
meda brand over-the-counter busi specialti drug franchis includ dermatolog respiratori allergi
along strength differ geograph region includ china russia asian countri
provid signific intern growth opportun
market profil world-wide gener drug market estim billion
account global drug market gener market boost recent year
rise demand inexpens gener throughout world larg number brand drug
recent lost patent protect allow gener competit gener account
prescript dispens repres total
pharmaceut sale dollar accord iqvia reflect much lower price gener versu
financi trend sale aid sever acquisit rose billion billion
repres three-year compound annual growth rate compound-annual-growth-rate howev sale fell
versu advers impact sever gener drug price deflat due intens
competit consolid downstream custom adjust pre-tax incom per share grew
declin repres three-year compound-annual-growth-rate
despit challeng environ gener drug maker recent year leverag
maintain safe level view debt-to-ebita earn interest tax
amort averag ebita-to-interest averag better gener
redistribut reproduct prohibit without prior written permiss copyright cfra
base cfra proprietari quantit model
stock rank overvalu
analysi stock current worth base
cfra proprietari quantit model suggest
slightli overvalu usd
neutral sinc march technic indic
neutral
figur base fiscal year-end price
growth rate averag
lt debt capit
return equiti
balanc sheet data million usd
oper
long term debt capit
net incom revenu
return asset
return equiti
 global market intellig data may preliminari restat result discontinu operations/speci item per share data adjust stock dividend ep dilut
redistribut reproduct prohibit without prior written permiss copyright cfra
outlook pharmaceut sub-industri
next year posit reflect
strong novel drug approv activ food
 drug administr fda
-- posit brand drug
maker repres lion share
sub-industri market cap also expect
stabil gener profit margin
competit appear moder
modest growth overal prescript
banner year brand drug
fda new drug approv
repres continu recent surg
approv shatter previou
record-high approv set
year dwarf approv
mani new drug littl
competit provid tailwind
brand drug sale addit
novel drug approv rare
diseas receiv fda orphan statu
mean receiv seven year competit
exclus indic think
provid boost long-term brand
side sub-industri
outlook earn growth gener maker
posit closer neutral fda gener
approv total
mani
compet version gener enter
sever gener
price deflat becam norm profit margin
contract surprisingli number
firm announc asset divestitur exit
 gener industri
bright side remain gener
maker think exit start
impact gener approv
tick vs first materi
declin least six year also note
move averag gener
applic lead indic view
recent high march
think anoth sign mitig
competit help slow gener
deflat yoy februari
versu yoy worst deflat
month think moder gener
deflat allow stabil gener
profit margin year ahead
anoth boost gener maker
record year fda first-gener approv
first-gener typic enter market
materi lower price brand
counterpart temporari protect
gener competitor allow
quick market share gain accordingli
recent increas first-gener provid
revenu tailwind gener maker
bolster posit outlook
sub-industri expect continu
growth prescript volum year
ahead recent growth health-insur
popul driven solid
employ growth
view think gain continu
strong labor market pull peopl onto
employee-sponsor health plan
like seek fill prescript
also think wave babi boomer age
prime drug-util year support
long-term growth drug volum
drop
year-to-d march
pharma index rose gain
base index
five-year market price perform may
note sector sub-industri inform base
past perform indic futur perform
reli upon
yield equiti
ltd
peer group compani stock select issu base market capit
note peer select base global industri classif standard market capit peer group list includ compani similar characterist may includ compani within
industri and/or engag line busi
redistribut reproduct prohibit without prior written permiss copyright cfra
keep target ep
estim histor averag forward price-to-earnings near see
continu challeng custom consolid risk multipl
govern investig maintain ep estim
initi share current low due struggl
last two year loss epipen price power gener price deflat
regulatori problem manufactur site think worst day
howev forecast improv profit margin competit
gener industri appear mitig fda gener approv track
decreas mark first declin sinc think lead
potenti turnaround industri earn remain focus
 downturn mani competitor pull back also see
adequ margin safeti legal risk given histor low valuat /colin
rais target ep
estim -- histor averag forward price-to-earnings see volum
price pressur continu ep vs
consensu keep ep estim drop
sale yoy led north america na total
drop yoy drop na sale mainli due lower volum relat
fda remedi action requir morgantown wv product site well
increas competit epipen adj oper margin improv howev
mainli reduct sg expens
reduct expens adj pre-tax incom yoy
remain cautiou share yet convinc declin
revenu trend stabil note see stabil
gener price environ think deflat may continu
/colin scarola
analyst research note compani news
pm et cfra maintain strong buy opinion share
lower target price ep estim
-- histor forward price-to-earnings averag due intens price pressur
gener drug drop ep estim
ep vs beat consensu revenu
declin yoy north america sale total europ
fall yoy respect due rapidly-grow sale new
complex gener biosimilar fail off-set declin commodity-lik
gener rest world sale total grew yoy strong growth
china sale growth well expect still think
revenu increas vs strong ramp gener advair
biosimilar neulasta sever new launch continu
think share attract valu low end guidanc
repres yield current market cap growth expect
long-term /colin scarola
pm et cfra rais sector overweight
marketweight cfra rais
sector overweight marketweight market valuat
expand sector trade discount histor averag cfra
find opportun within health care sector trade forward
price-to-earnings basi histor averag first quarter
compani health care sector beat sale
earn estim best perform index biotech
pharmaceut compani account market capit
sector drug pipelin approv time reduct activ make
industri attract care histori outperform
season slow period year may octob cfra
forecast sector like disappoint lindsey bell
et cfra maintain strong buy opinion share
lower target ep
estim -- histor forward price-to-earnings averag due price
headwind custom consolid drop ep estim
ep vs
consensu sale fell yoy driven declin north
america total lower volum continu gener price deflat
expect long-term invest complex gener biosimilar start
pay year howev forecast sale growth sever
new product ramp though requir increas
market spend gain share think hurt ep
ultim produc attract long-term growth market current
undervalu prospect view estim free
cash flow yield attract today market cap expect
grow substanti start /colin scarola
pm et cfra upgrad opinion share strong buy
buy keep target
ep estim histor forward price-to-earnings averag due continu
headwind custom consolid risk govern investig
maintain ep estim believ
well-posit benefit potenti stabil gener
drug market recent peak around januari
six-month move averag fda gener drug applic fell
novemb latest data think result competitor scale back
gener oper could lead improv margin next two
year also expect gener industry-averag ep growth due
strategi focus gener biosimilar develop complex
high-barri brand drug sustain margin growth prospect
adequ margin safeti legal risk also exist view given
et cfra upgrad opinion share buy hold
note research note reflect cfra publish opinion analysi stock time note publish note reflect view equiti analyst date time
indic note may reflect cfra current view compani
redistribut reproduct prohibit without prior written permiss copyright cfra
fiscal year analyst estim earn
usd fiscal year analyst estim
earn per share grow usd
total
estimate
forecast reliabl indic futur perform
note compani earn outlook play major part invest decis global market intellig organ earn estim wall street analyst
provid consensu earn next two year well earn estim chang time note inform provid relat consensu
estim intend predict actual result taken reliabl indic futur perform
note tabl graph chart report cite refer sourc sourc global market intellig
redistribut reproduct prohibit without prior written permiss copyright cfra
sinc januari cfra equiti fund research servic
predecessor capit iq equiti research rank univers
common stock adr american depositari receipt adss american
depositari share base given equiti potenti futur perform
similarli rank asian european equiti sinc june
rank equiti accord individu forecast equiti futur total
return potenti versu expect total return relev benchmark
region index asia europ
base time horizon star design meet need
investor look put invest decis perspect data use
assist determin star rank may result analyst
model well intern proprietari model result dynam data
also known
 growth
stabil earn dividend deem key element establish
global market intellig earn dividend rank common stock
design capsul natur record singl symbol
note howev process also take consider certain
adjust modif deem desir establish rank
final score stock measur score matrix determin
analysi score larg repres sampl stock
rang score array sampl align follow
ladder rank
cfra earn per share ep estim reflect analyst project futur
ep continu oper gener exclud variou item
view special non-recur extraordinari also ep estim reflect
either forecast equiti analyst consensu averag ep estim
independ compil global market intellig data
provid cfra among item typic exclud ep estim
asset sale gain impair restructur merger-rel charg legal
insur settlement process research develop expens gain
loss extinguish debt cumul effect account
chang earn relat oper classifi
compani discontinu inclus item stock option
expens recur type charg may vari depend
factor industri practic analyst judgment extent
type data disclos compani
equiti analyst project market price given secur command
month henc base combin intrins rel privat
cfra equiti research produc distribut account research
analyt llc d/b/a cfra cfra us togeth affili
subsidiari cfra certain research produc distribut cfra
sdn bhd compani formerli known standard poor
malaysia sdn bhd cfra malaysia certain research distribut cfra uk
limit cfra uk cfra uk cfra malaysia wholly-own subsidiari
cfra us
abbrevi use equiti research report
ebit earn interest tax
redistribut reproduct prohibit without prior written permiss copyright cfra
p/nav price net asset valu ratio price-to-earnings-to-growth ratio pv present
 research develop roce return capit employ roe
return equiti
roi return invest
 return invest capit
roa return asset
wacc weight averag capit
dividend american depositori receipt adr american depositori
share adss net tax paid countri origin
reflect equiti analyst view given compani oper risk
risk firm abil continu on-going concern qualit risk
assess rel rank star univers
reflect risk factor relat compani oper oppos risk
volatil measur associ share price etf reflect
capitalization-weight basi averag qualit risk assess
assign hold fund
star rank system definit
total return expect outperform total return relev benchmark
notabl margin come month share rise price
total return expect outperform total return relev benchmark
come month share rise price absolut basi
total return expect close approxim total return relev
benchmark come month share gener rise price
absolut basi
total return expect under-perform total return relev
benchmark come month share price anticip
total return expect under-perform total return relev
benchmark notabl margin come month share fall
price absolut basi
north america relev benchmark europ
asia relev benchmark europ asia
